ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,592Medicare Part D Prescriptions Filled, Including Refills

Rank: 6 out of 153

$461K Total Retail Price of All Prescriptions

Rank: 12 out of 153

351 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
70% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Wyoming
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 351 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

21% of this provider’s 351 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

1% of this provider’s 9,258 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$44 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Wyoming
LEVOTHYROXINE SODIUM 559 523 1 1
FUROSEMIDE 479 441 2 6
WARFARIN SODIUM 463 437 3 10
OMEPRAZOLE 394 385 4 4
CITALOPRAM HBR 382 314 5 14
LISINOPRIL 347 328 6 3
POTASSIUM CHLORIDE 346 325 7 12
HYDROCODONE-ACETAMINOPHEN 275 254 S3 8 5
SERTRALINE HCL 241 194 9 16
AMLODIPINE BESYLATE 222 207 10 7
POLYETHYLENE GLYCOL 3350 204 191 11 41
METFORMIN HCL 192 155 12 8
NAMENDA 178 178 13 28
HYDROCHLOROTHIAZIDE 175 172 14 9
METOPROLOL TARTRATE 169 169 15 11
DONEPEZIL HCL 168 168 16 26
ATENOLOL 129 126 17 18
DIGOXIN 127 127 18 40
METOPROLOL SUCCINATE 124 107 19 13
SIMVASTATIN 124 104 19 2
CIPROFLOXACIN HCL 120 103 21 72
CARBIDOPA-LEVODOPA 108 108 22 91
GABAPENTIN 103 94 23 15
QUETIAPINE FUMARATE 101 100 24 57
OLANZAPINE 97 96 25 85
ZOLPIDEM TARTRATE 91 59 26 21
CEPHALEXIN 89 79 27 73
ALLOPURINOL 81 60 28 25
ENALAPRIL MALEATE 81 81 28 42
OXYBUTYNIN CHLORIDE ER 80 80 30 78
PANTOPRAZOLE SODIUM 77 58 31 30
TAMSULOSIN HCL 76 76 32 24
LOSARTAN POTASSIUM 76 67 32 17
IPRATROPIUM-ALBUTEROL 74 71 34 110
FLUTICASONE PROPIONATE 74 54 34 38
ADVAIR DISKUS 65 53 36 31
RANITIDINE HCL 65 65 36 53
LANTUS 62 54 38 44
CARVEDILOL 61 48 39 36
CYCLOBENZAPRINE HCL 61 39 R 39 59
MELOXICAM 60 53 41 27
FAMOTIDINE 57 42 42 54
SEROQUEL 57 57 42 143
FLUCONAZOLE 55 45 44 145
AZITHROMYCIN 51 43 45 43
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 16, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.